Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies

Core Insights - AVITA Medical presented data from 19 scientific abstracts at the 2026 Boswick Burn & Wound Symposium, showcasing the integrated use of its technologies RECELL, PermeaDerm, and Cohealyx in wound care [1][2][3] Group 1: Integrated Use of Technologies - The first surgeon-reported experience integrating RECELL, PermeaDerm, and Cohealyx was highlighted, demonstrating reduced need for painful dressing changes and avoiding long-distance follow-ups [3] - This integrated approach is particularly beneficial for rural and community hospitals with limited access to specialized burn services [3] Group 2: Clinical Findings - Initial findings from multicenter clinical trials on PermeaDerm and Cohealyx were presented, with full results expected in 2026 [4] - PermeaDerm showed early blood vessel growth and organized tissue formation without increased inflammation compared to traditional human skin for temporary coverage [5] - Cohealyx demonstrated cellular infiltration and early blood vessel formation within two weeks, preparing the wound for skin grafting without complications [6] Group 3: RECELL Evidence and Benefits - A systematic review of 27 peer-reviewed studies reinforced the benefits of RECELL, showing consistent trends in healing, reduced complications, and shorter hospital stays [7][10] - In older burn patients, adding RECELL to standard skin grafting resulted in nearly 16 days shorter hospital stays and fewer graft failures [9] - Patients treated with RECELL for deep partial-thickness burns spent about one-third less time in the hospital compared to traditional grafting methods [9] Group 4: Practical Applications - Surgeons are demonstrating how the staged use of AVITA Medical's advanced wound care technologies can improve healing and help hospitals manage limited resources [11]